ConductScience.org, home

Comparison · NCT01488578-df1e0f06

With BPH vs Without BPH: Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Tolterodine - Comorbidity of Prostatic Hypertrophy

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. With BPH vs Without BPH: Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Tolterodine - Comorbidity of Prostatic Hypertrophy. Trial comparisons, record NCT01488578-df1e0f06. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01488578-df1e0f06

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1450.1310.16wilson
Risk in group 20.07010.05930.0826wilson
Risk difference, group 1 minus group 20.07470.05590.0934newcombe hybrid score
Risk ratio, group 1 over group 22.071.72.51log
Odds ratio, group 1 over group 22.251.812.78log
Number needed to treat, for one more participant with the outcome on With BPH than on Without BPH13.410.717.9from the risk difference interval

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1With BPHParticipants with complication of benign prostatic hypertrophy who took tolterodine according to Japanese Package Insert.3192,203OG000
Group 2Without BPHParticipants without complication of benign prostatic hypertrophy who took tolterodine according to Japanese Package Insert.1301,855OG001

Outcome

Type
SECONDARY
Title
Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Tolterodine - Comorbidity of Prostatic Hypertrophy
Description
Number of participants with Treatment Related Adverse Events (TRAEs) of tolterodine to determine whether with or without comorbidity of benign prostatic hypertrophy (BPH) is significant risk factor.
Time frame
12 week
Population
The safety analysis population consists of the cases that satisfy the participants conditions and in whom administration of this drug was confirmed.

Source ClinicalTrials.gov

Trial

Title
Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)
NCT number
NCT01488578
Phases
Conditions
Overactive Bladder
Interventions
Tolterodine tartrate
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Results first posted
2012-06-14

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01488578-df1e0f06